Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Reload Before Percutaneous Coronary Intervention: Reperfusion Indexes Evaluation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* De novo native coronary chronic occlusion with a reference diameter equal or superior to 3 mm programmed treatment;~* 100 mg/die oral aspirin treatment for at least 7 days before the procedure;~* Target lesion must be covered with two stent maximum with a maximum length ≤ 33 mm each~* Signed written informed consent~Exclusion Criteria:~* Aspirin, bisulphate clopidogrel, ticlopidine, heparin, contrast agent or heavy metals known allergy that cannot been medically handled;~* Target occlusion localized inside a previously implanted graft~* Target occlusion localized inside a vessel segment previously underwent stent-positioning~* Target occlusion localized inside a vessel with other occlusion not-to-be treated with the target occlusion same stent(s)~* Target occlusion localized inside a vessel with other occlusions need to be treated with balloon angioplasty~* Other techniques than balloon angioplasty target occlusion pre-treatment such as atherectomy, laser intervention or thrombectomy~* Coronary brachytherapy treated patients~* Ejection fraction equal or minor to 30%~* Renal insufficiency (creatinine \>3.0 mg/dl)~* Warfarin-treated patients~* Life expectancy minor to 12 months~* Heart transplanted patients~* Patients still enrolled in some other study, both pharmacological both not

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: ACTIVE_COMPARATOR): All patients who meet the eligibility criteria will be randomized in a 1:1 manner to receive, before the coronary percutaneous procedure, an oral aspirin reload (325 mg)or placebo.
- No intervention (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).